Take Action: Tell your senators to reject harmful cuts to health care!
The Medicare Rights Center commented on the Contract Year 2025 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly proposed rule.
Medicare Rights comments on medically necessary dental and mental health and substance use disorder provisions in the 2024 Physician Fee Schedule.
Medicare Rights comments in support of provisions in the Short-Term, Limited-Duration Insurance proposed rule.
Medicare Rights comments in support of the Health and Human Services Grants Regulation proposed rule.
These comments from the Medicare Rights Center are in support of separate licensing standards for relative or kinship foster family homes.
Medicare Rights comments in support of removing food from the calculation of in-kind benefits for Supplemental Security Income (SSI).
Callers to our national helpline regularly report struggling to afford the prescription medications they need to maintain their health and well-being. The Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program could offer much-needed relief. In our comments, we offer recommendations to implement this program in a way that enhances affordability, ensures accuracy, and maximizes transparency.
The Medicare Rights Center (Medicare Rights) appreciates this opportunity to comment on the Advancing Interoperability and Improving Prior Authorization Processes proposed rule.
Prior authorization is creating an ever-increasing burden on patients. We support many of the Centers for Medicare & Medicaid Services (CMS) provisions in this proposed rule that would reduce this burden by improving processes, timelines, access to information, and communication.
Medicare Rights applauds CMS for proposing to extend Medicare coverage of power seat elevation. This feature is critical to promoting beneficiary health, safety, and independence.
The Inflation Reduction Act’s (IRA) Rebate Program will require drug companies to pay a rebate if they raise certain Part D drug prices faster than inflation, reining in the industry practice of sky-high annual price adjustments. This deterrent will strengthen beneficiary and program finances.
